問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

List

2245Cases

2025-09-15 - 2030-12-31

Active
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial investigating the efficacy and safety of TRONTINEMAB in patients with early symptomatic Alzheimer's disease (mild cognitive impairment to mild dementia caused by Alzheimer's disease).

  • Condition/Disease

    Changes in CDR-SB from the base period to week 72

  • Test Drug

    trontinemab

Participate Sites
8Sites

Recruiting8Sites

2025-09-22 - 2029-03-18

Active
The master plan for an open-label, multi-drug, multicenter, phase II trial evaluates the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity (LIBRA) of a novel combination therapy in participants with locally advanced or metastatic non-small cell lung cancer.

  • Condition/Disease

    • Safety: Number of participants experiencing adverse events (AEs) and serious adverse events (SAEs). • Efficacy: Objective response rate (ORR).

  • Test Drug

    Dato-DXd Rilvegostomig Xinruize

Participate Sites
9Sites

Recruiting9Sites

2025-09-24 - 2028-11-30

Phase I

Active
A first-in-human, phase 1, open-label, multicenter trial of a novel phosphatidylinositol glycan-3 target antibody-drug complex, ZW251, in participants with advanced solid tumors including hepatocellular carcinoma.

  • Condition/Disease

    Including advanced solid tumors such as hepatocellular carcinoma

  • Test Drug

    ZW251

Participate Sites
3Sites

Recruiting3Sites

2025-10-01 - 2030-06-30

Active
EASi-PROTKT™ is a phase III, double-blind, randomized, parallel-group superiority trial evaluating the efficacy and safety of oral vicadrostat (BI 690517) combined with empagliflozin compared to placebo combined with empagliflozin in participants with type 2 diabetes, hypertension, and a history of cardiovascular disease.

  • Condition/Disease

    • The time elapsed before the first occurrence of a CV death or HFE (defined as HHF or emergency HF visit). CV deaths include deaths of unknown cause.

  • Test Drug

    BI 690517 (Vicadrostat) or matching placebo Empagliflozin

Participate Sites
13Sites

Recruiting13Sites

2025-10-01 - 2035-01-20

Active
Beamion LUNG-3: A randomized, controlled, multicenter trial evaluating zongertinib as adjuvant monotherapy versus standard of care in patients with early-stage, resectable non-small cell lung cancer (stage II-IIIB) and HER2 mutations with activated tyrosine kinase domain.

  • Condition/Disease

    DFS as assessed by the trial administrator. DFS is defined as the time elapsed from randomization until tumor recurrence or death from any cause (whichever occurs earlier).

  • Test Drug

    Imfinzi® KEYTRUDA® OPDIVO Tecentriq® Zongertinib (BI 1810631)

Participate Sites
6Sites

Recruiting6Sites

2025-10-01 - 2031-04-30

Phase III

Active
TRITON-PN: A phase 3, global, randomized, open-label trial evaluating the efficacy and safety of nucresiran in patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN).

  • Condition/Disease

    Patients with hereditary transthyretin transporter amyloid polyneuropathy (hATTR-PN)

  • Test Drug

    Nucresiran (ALN-TTRSC04) vutrisiran (ALN-TTRSC02)

Participate Sites
3Sites

Recruiting3Sites

2025-02-07 - 2032-12-31

Phase I/II

Active
A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

  • Condition/Disease

    Esophageal Squamous Cell Carcinoma

  • Test Drug

    凍晶注射劑 注射劑 注射劑 注射劑 注射劑 注射劑

Participate Sites
8Sites

Recruiting8Sites

2025-02-11 - 2038-02-19

Phase III

Active
AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    錠劑 錠劑 膠囊劑 錠劑 錠劑 錠劑

Participate Sites
8Sites

Recruiting8Sites

2025-02-01 - 2032-12-31

Phase III

Active
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor and Letrozole in Patients With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Tablets Film-coated tablets Film-coated tablets Film-coated tablets Film-coated tablets

Participate Sites
6Sites

Recruiting6Sites

2025-11-01 - 2029-05-31

Phase III

Active
An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

  • Condition/Disease

    Chronic Kidney Disease

  • Test Drug

    Tablets Tablets Granules for suspension Granules for suspension

Participate Sites
6Sites

Recruiting5Sites

1 2 3 4 5 225
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB